For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort ...

In some with grade 3 brain cancer, adding PCV chemotherapy regimen to radiation showed better survival outcomes than another ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...

Discover key gene signatures that could help predict the efficacy of immune checkpoint blockade therapy in patients with ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer overall and progression-free survival, according to a study published online ...

Biodexa (NASDAQ:BDRX) reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma, an aggressive cancer of the ...